Effects of Inhaled Cannabis on Driving Performance

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to expand understanding of the effects of cannabis on driving performance with and without the presence of low levels of alcohol.

This project will involve the development a of a protocol and driving environment that is sensitive to the effects of cannabis on driving performance by building on prior driving situations used previously for testing the effects of alcohol on driving.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests

NCT05273658

Driving Impaired Alcohol Intoxication Driving Under the Influence +1 more

WITHDRAWN PHASE1/PHASE2

Marijuana Effects on Simulated Driving Performance

NCT03699540

Cannabis Cannabis Use Marijuana +2 more

COMPLETED PHASE1

Effects of THC and Alcohol on Driving Performance

NCT03555968

Cannabis Alcohol Drinking Accident, Traffic

WITHDRAWN PHASE4

Alcohol Effects on Driving-related Skills of Young Drivers

NCT02710578

Psychomotor Impairment

COMPLETED NA

Combined Alcohol and Cannabis Effects on Skills of Young Drivers

NCT03106363

Psychomotor Impairment

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Individuals will be recruited who are currently users of cannabis and alcohol to participate in this study. They will undergo a physical exam at screening. There will be six study visits where the subject will arrive at the Clinical Research Unit(University of Iowa Hospitals \& Clinics) the night before dosing. At each visit subjects will be receive one of the following six dosing regimens: placebo alcohol with placebo cannabis; placebo alcohol with low-dose cannabis, placebo alcohol with higher-dose of cannabis, low dose alcohol with placebo cannabis; low dose alcohol with low dose cannabis, low dose alcohol with higher-dose of cannabis. After dosing, participants will have provide saliva samples and blood drawn periodically to check cannabis levels and will complete a driving simulation. After completing the drive, additional saliva samples and blood draws will occur and participants will be monitored until it is safe to transport home.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Drinking Cannabis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0% THC with 0.065 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

2.5-3.5% THC with 0.065 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

6.0-7.5% THC and 0.065 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

2.5-3.5% THC with 0 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

6.0-7.5% THC with 0 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

0% THC with 0 g/dL BAC

Group Type EXPERIMENTAL

Alcohol(oral) and placebo

Intervention Type DRUG

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Cannabis(THC)(Inhaled) and Placebo

Intervention Type DRUG

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alcohol(oral) and placebo

Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive

Intervention Type DRUG

Cannabis(THC)(Inhaled) and Placebo

Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ethanol Ethyl Alcohol Marihuana Marijuana

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult (age 21-55) men and women, based on medical and psychological evaluation
* Currently valid unrestricted (except for vision correction) US driver's license
* Licensed driver for at least the past two years
* Drove at least 1300 miles in the past year, by self-report
* Live within an 80 mile radius of NADS
* Available for an overnight stay followed by a full-day study session for six sessions
* Must be considered a light or moderate drinker according to Quantity-Frequency-Variability Scale (QFV)
* Cannabis use with a minimum frequency averaging at least one day per quarter and no more than three days a week during the three months prior to study entry
* Peripheral veins suitable for repeated venipuncture and/or placement of an intravenous catheter
* Systolic blood pressure within a clinically normal range (120 ± 30 mmHg) and -diastolic blood pressure of 80 ± 20 mmHg..
* Good command of written and spoken English
* Female subjects with reproductive potential must agree to use (and/or have their partner use) one (1) acceptable method of birth control beginning at the screening visit throughout the study (including intervals between treatment periods/panels) and until 2 weeks after the last dose of study drug in the last treatment period. Acceptable methods of birth control include the following: intrauterine device (IUD-with or without local hormone release), diaphragm, spermicides, cervical cap, contraceptive sponge, oral contraceptives or condoms. Abstinence is an alternative lifestyle and subjects practicing abstinence may be included in the study.

Exclusion Criteria

* Presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might influence driving performance (e.g., seizures, sleep apnea, narcolepsy, vertigo, chronic fatigue syndrome) or put the subject at increased risk of adverse events (e.g., cardiac arrhythmia, hypertension)
* History of a clinically significant adverse event associated with cannabis or alcohol intoxication
* Donation of more than 450 mL of blood within 14 days of study drug administration
* If female, pregnant or nursing
* Currently interested in or participating in drug abuse treatment, or participated in drug abuse treatment within 60 days preceding study enrollment
* Currently taking drugs that are contraindicated for use with study drugs
* Requires any special equipment to aid in driving (ex. pedal extensions, hand brake or throttle, spinner wheel knobs or other non-standard equipment)
* Significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening (SSQ). Subjects must have scores below the following values on the SSQ: Nausea \< 21, Oculomotor \<32, Disorientation \< 15, and Total Score \< 32.
* Current alcohol or cannabis use disorder, as identified by the Alcohol Use Disorders Identification Test for alcohol or Cannabis Use Disorders Identification Test for cannabis.
* History of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject from study participation
* Prior participation in a driver impairment or distraction-related research study conducted at NADS that uses the same base drive.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes